Figure 4.

Comparison of bone mineral density, pyridinoline (PD), and deoxypyridinoline (DPD) values before and after treatment with dexamethasone and the phosphodiesterase-5 (PDE-5) inhibitors, avanafil and zaprinast. (A) The radiologically measured values of bone mineral density (BMD) (g/cm²). (B) Urine pyridinoline (PD) values (nmol/mL). (C) Urine deoxypyridinoline (DPD) values (nmol/mL). * p<0.05: when compared with the control group after the administration of dexamethasone and the phosphodiesterase-5 (PDE-5) inhibitor. ^# p<0.05: when compared with the other groups after the administration of dexamethasone and the phosphodiesterase-5 (PDE-5) inhibitor. ^@ p<0.05: when compared with the administration of dexamethasone and the phosphodiesterase-5 (PDE-5) inhibitor in the same group. ^a p<0.05: when compared with the other groups before the administration of dexamethasone and the PDE-5 inhibitor in the same group.